The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented important advances in genitourinary oncology. During a resident-led Post-ASCO GU 2026 meeting supervised by genitourinary oncology experts, clinically relevant studies were selected and critically discussed. This report reviews PROTEUS and TALAPRO-3 in prostate cancer; RAMPART and the KEYNOTE-564 circulating tumor DNA analysis in renal cell carcinoma; and POTOMAC, EV-302/KEYNOTE-A39, EV-303, and NEXUS-01 in urothelial carcinoma. These studies highlight the growing roles of perioperative systemic therapy, biomarker-guided treatment, antibody–drug conjugates, and patient-reported outcomes. Their clinical implications vary according to study design and evidence maturity: some reinforce established standards, whereas others support potential future strategies or remain hypothesis-generating. Although its educational impact was not formally assessed, the initiative provided a structured setting for discussing and critically appraising emerging congress evidence.
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology / Izzi M., Shtembari K., Specchiarello S., Calandrelli C., Mancini S., Mela M.M., Rossi V., Giorgione R., Rossini D., Pillozzi S., Antonuzzo L., Roviello G.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - ELETTRONICO. - (2026), pp. 1-5. [10.1080/14796694.2026.2742677]
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology
Izzi M.;Shtembari K.;Specchiarello S.;Calandrelli C.;Rossini D.;Pillozzi S.;Antonuzzo L.;Roviello G.
2026
Abstract
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented important advances in genitourinary oncology. During a resident-led Post-ASCO GU 2026 meeting supervised by genitourinary oncology experts, clinically relevant studies were selected and critically discussed. This report reviews PROTEUS and TALAPRO-3 in prostate cancer; RAMPART and the KEYNOTE-564 circulating tumor DNA analysis in renal cell carcinoma; and POTOMAC, EV-302/KEYNOTE-A39, EV-303, and NEXUS-01 in urothelial carcinoma. These studies highlight the growing roles of perioperative systemic therapy, biomarker-guided treatment, antibody–drug conjugates, and patient-reported outcomes. Their clinical implications vary according to study design and evidence maturity: some reinforce established standards, whereas others support potential future strategies or remain hypothesis-generating. Although its educational impact was not formally assessed, the initiative provided a structured setting for discussing and critically appraising emerging congress evidence.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



